leadf
logo-loader
viewReNeuron Group PLC

ReNeuron encouraged by progress in stroke and RP treatments

Snapshot

  • Developer of stem cell technologies
  • Has two clinical stage technologies
  • Stroke treatment in Phase IIb trials
dna strand

Quick facts: ReNeuron Group PLC

Price: 102.5 GBX

LSE:RENE
Market: LSE
Market Cap: £58.28 m
Follow

 

What the company does

Human retinal progenitor cells (hRPC)

Human retinal progenitor cells differentiate into components of the retina. 

Reneuron has developed the ability to scale up the manufacturing of hRPCs using a patented low-oxygen cell expansion technology.

The hRPC cell therapy candidate is being evaluated in an ongoing phase I/IIa clinical trial in the US in subjects with a blindness-causing inherited retinal disease, retinitis pigmentosa (RP). 

CTX Cells 

 CTX cell therapy candidate is a treatment for patients left disabled by the effects of a stroke. 

Reneuron’s product is a standardised, clinical and commercial-grade cell therapy product capable of treating all eligible patients presenting with the diseases targeted, without the need for additional immunosuppressive drug treatments. 

Data from the Phase II PISCES trial indicated CTX therapy was safe and well-tolerated and produced clinically meaningful and sustained improvement in the level of disability and dependence as well as motor function.

Exosome platform

Exosomes are nanoparticles, released by cells, and contain a number of active proteins and micro RNAs, which are short non-coding RNAs capable of regulating gene expression, that are believed to play a key role in cell-to-cell communication.

ExoPr0, Reneuron’s  first CTX-derived exosome therapeutic candidate, has demonstrated potential as both a novel therapeutic candidate as well as a drug delivery vehicle

 

How it is doing

In September it began dosing in the US for the expanded phase IIa trial of its hRPC cell therapy for the degenerative eye condition retinitis pigmentosa (RP).

ReNeuron expects to present further data over the next 12 months and it believes it will be able to compile enough clinical evidence in that time to seek approval in the second half of next year for a single pivotal clinical trial.

The US Food & Drug Administration (FDA) has also given the hRPC treatment fast-track status, which means it may be eligible for accelerated approval.

 

What the boss says: Olav Hellebø, chief executive

"The decision we have recently taken to focus our in-house activities on our retinal disease and exosome-based programmes provides the company with significant near-term opportunities to deliver value-enhancing data and commercial partnerships.”

“Our stroke disability programme will continue through regional partnerships and we are pleased to be working with Fosun Pharma as our partner for China, following the signing of the exclusive licence agreement for both our CTX and hRPC programmes in that territory during the period."

 

Video

 

Inflexion Points

  • On the CTX front, a Phase IIb trial, called PISCES III, is underway.
  • The results from this trial are expected in the first half of 2021 because patient recruitment has been slower than anticipated due to the nature and complexity of the study.
  • ReNeuron remains in negotiations with potential partners for all of its key programmes.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read